Breakthroughs in Cancer Gene Therapy: Nucleic Acid Therapies Show Promise

Strategic Insights -

New research out of India has shed light on the immense potential of cancer immunotherapy, with a focus on nucleic acid therapies that can modify immune responses and change the expression of target genes. According to a study published in the journal Advances in Immunology, the development of nanoparticle delivery methods has addressed several challenges in delivering nucleic acid therapies to immune cells, making them a promising approach for immunotherapy against cancer. The research highlights the diverse capabilities of nucleic acid therapies, including gene-editing guide RNA, immunomodulatory DNA/RNA, messenger RNA, microRNA, and siRNA, which can be used to modify immune responses and change the expression of target genes.

Key Takeaways:

  • The number of immuno-oncology medication approvals has increased in recent years, indicating the potential of cancer immunotherapy.
  • Nucleic acid therapy has advanced significantly in recent years, with diverse capabilities including gene-editing guide RNA, immunomodulatory DNA/RNA, messenger RNA, microRNA, and siRNA.
  • Nanoparticle delivery methods have addressed several challenges in delivering nucleic acid therapies to immune cells, making them a promising approach for immunotherapy against cancer.
  • The study highlights the importance of overcoming delivery challenges, such as quick in vivo disintegration, inadequate absorption inside target cells, and possible in-vivo toxic potential in healthy tissues and cells.
  • The research concluded that nucleic acid applications for medicines used for immunotherapy against cancer are covered in this chapter, along with the development of nanoparticle platforms that carry genome editing, mRNA, and DNA systems for improving the efficacy and safety profile in various therapies.
  • The study has been peer-reviewed and published in the journal Advances in Immunology.

Statistics:

  • The number of immuno-oncology medication approvals has increased significantly in recent years, indicating the potential of cancer immunotherapy.
  • The study highlights the diversity of nucleic acid therapies, including gene-editing guide RNA, immunomodulatory DNA/RNA, messenger RNA, microRNA, and siRNA.
  • The development of nanoparticle delivery methods has improved the safety and efficacy of nucleic acid therapies, making them a promising approach for immunotherapy against cancer.

Sources:

  • Nucleic acid delivery as a therapeutic approach for cancer immunotherapy. Advances in Immunology, 2024;165:37-62.
  • Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, Haryana, India.
  • Elsevier Academic Press Inc, 525 B Street, Suite 1900, San Diego, CA 92101-4495, USA.